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http://www.biomedcentral.com/1471-2377/12/29RESEARCH ARTICLE Open AccessTowards a definition of refractory neuropathic
pain for epidemiological research. An
international Delphi survey of experts
Blair H Smith1*, Nicola Torrance1, Janice A Ferguson1, Michael I Bennett2, Michael G Serpell3 and Kate M Dunn4Abstract
Background: Best current estimates of neuropathic pain (NeuP) prevalence come from studies using various
screening detecting pain with probable neuropathic features; the proportion experiencing significant, long-term
NeuP, and the proportion not responding to standard treatment are unknown. These “refractory” cases are the
most clinically important to detect, being the most severe, requiring specialist treatment.
Methods: We report an international Delphi survey of experts in NeuP, aiming for consensus on the features
required to define, for epidemiological research: (1) neuropathic pain; and (2) when NeuP is “refractory”. A web-
based questionnaire was developed and data collected from three rounds of questionnaires from nineteen experts.
Results: There was good consensus on essential inclusion of six items to identify NeuP (“prickling, tingling, pins &
needles”, “pain evoked by light touch”, “electric shocks or shooting pain”, “hot or burning” pain, “brush allodynia on
self-examination”, and “relevant history”) and on some items that were non-essential. Consensus was also reached
on components of a “refractory NeuP” definition: minimum duration (one year); number of trials of drugs of known
effectiveness (four); adequate duration of these trials (three months / maximum tolerated); outcomes of treatment
(pain severity, quality of life). Further work needs to validate these proposed criteria in general population research.
Conclusions: This paper presents an international consensus on measuring the epidemiology of refractory
neuropathic pain. This will be valuable in reaching an agreed estimate of the prevalence of neuropathic pain, and
the first estimate of refractory neuropathic pain prevalence.
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Studies have examined the prevalence, distribution and
determinants of specific conditions associated with
neuropathic pain (NeuP), notably postherpetic neuralgia
(PHN) and painful diabetic neuropathy (PDN) [1]. How-
ever, the overall population prevalence of NeuP remains
unknown, and factors associated with its onset and re-
covery are poorly understood. Prevalence estimates of
1–2% [2,3] are inaccurate (as they are extrapolated from
assumptions relating to specific conditions) and are
probably under-estimates [4], as they do not include* Correspondence: b.h.smith@dundee.ac.uk
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reproduction in any medium, provided the orundiagnosed NeuP or cases where neuropathic features
contribute importantly to pain of mixed mechanism [5].
The current best population estimates for NeuP come
from studies using screening instruments that detect pain
with probable neuropathic features. One of these, using
the S-LANSS, found a prevalence of “pain of predomin-
antly neuropathic origin” (POPNO) of 8.2% [6]. Another,
using the DN4, found a prevalence of “chronic pain with
neuropathic characteristics” of 6.8% [7]. Using the Pain-
DETECT questionnaire, Freynhagen et al [8] estimated
that 11.4% of males had low back pain with a predomin-
antly neuropathic component. Differences in these and
other estimates are partly accounted for by differences in
the way in which NeuP is defined by the different instru-
ments, which were originally defined for clinical purposes
[9]. Whilst there is no ideal epidemiological method fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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examination is impractical in large population studies, and
other methods, such as reviewing medical records, are re-
liant on the quality and standard criteria of routine data
entry. There is therefore a need for consensus on a defin-
ition of NeuP for use in population research.
Neuropathic pain that is refractory to treatment
Among these relatively high reported prevalences, it is
unknown what proportion of individuals experience clin-
ically significant, long-term pain and/or pain that has
not responded to standard non-specialist treatment.
These “refractory” cases of NeuP are clinically the most
important to detect, as they are likely to be the most se-
vere and difficult to treat, use healthcare services more
often, and to be those who merit informed treatment
and follow-up targeted at NeuP. The term “refractory
neuropathic pain” has emerged recently in the literature,
[10-12] but definitions vary markedly. In a preliminary
attempt to review the epidemiology of refractory NeuP,
Taylor [12] used a search strategy with a broad definition
that included specific named NeuP conditions and pain
that was “persistent”. The Scottish Medicines Consor-
tium (SMC) describes patients with refractory NeuP as
those who “have not achieved adequate pain relief from,
or have not tolerated, conventional first and second line
treatments for neuropathic pain”, with specific prescrib-
ing implications [13]. In one randomised controlled trial
[11], refractory NeuP was defined as having had lasted at
least six months, with a pain severity score of at least
40 mm on a 0-100 mm visual analogue scale, and exhi-
biting no response to usual pharmacological care. There
is, however, neither consensus on these definitions, nor
critical review of their parameters.
Hansson et al. recently proposed a definition of “phar-
macoresistant” NeuP and a rational approach to prescrib-
ing efficacious drugs in order of precedence [14].
However, the authors concluded that the required scien-
tific evidence to confirm this definition is not yet available.
Furthermore, “refractory NeuP” and “pharmacoresistant
NeuP” may be clinically different entities. Attempts to dis-
tinguish between refractory and pharmacoresistant epi-
lepsy have proved challenging [15,16], with no final
consensus.
If refractory NeuP can be defined and classified in a
way that is agreed to be clinically and epidemiologically
relevant, it will be possible to identify individuals and
sub-groups within the community who experience this
most severe NeuP and are in greatest need of treatment.
This will in turn allow an assessment of the scale of the
problem, identification of risk factors for “refractoriness”
(including those that are potentially modifiable), and the
subsequent efficient targeting of management or preven-
tion strategies.The aims of this study were therefore to reach expert
consensus on the features required to define, for epi-
demiological research: (1) neuropathic pain; and (2)
when neuropathic pain is “refractory”. These features
should be able to be incorporated into a questionnaire
suitable for administration to large study samples.
Methods
Consensus of experts/the Delphi method
The Delphi technique has been used widely in medical
and nursing research as a survey method used to gain
consensus among a group of respondents [17-19]. The
technique involves asking a panel of experts to take part
in a series of consecutive rounds of questionnaires
designed to achieve increasing consensus of opinion. A
panel usually consists of 15 to 30 participants [18], be-
tween 12 and 20 being considered optimal [18,20]. Typ-
ically three rounds of questionnaires are sent to the
expert panel, although the decision over the number of
rounds is largely pragmatic and often varies between
two and four partly depending on the quality and rates
of response [20-22]. Participants’ responses are anon-
ymised to ensure that the influence of peer pressure on
respondents’ opinions is minimised [23]. A summary of
the results showing the distribution of the group’s re-
sponse and patterns of agreement of the previous round
are fed back to be evaluated by panel members [19,23].
Consensus can be said to be achieved when a given pro-
portion of participants are in agreement. This propor-
tion varies between studies, with some authors accepting
51% [24] whilst other have suggested levels of between
60% and 80% are required [17,25-27].
Participants
Internationally recognised experts on neuropathic pain
research were identified. These included authors of im-
portant published epidemiological and clinical studies,
and members of the Committee of the Neuropathic Pain
Special Interest Group (NeuP SIG) of the International
Association for the Study of Pain, who developed guide-
lines on the assessment of neuropathic pain [28]. These
individuals were approached by email with an invitation
to participate in the Delphi method survey. The final list
included 40 experts from 11 countries. To comply with
the conditions of ethical approval, the identities of
experts were kept confidential throughout the study and
beyond. We set a priori the level of agreement between
them at which consensus would be recognized as 70%,
recognizing that more than a simple majority would be
required but that the complexity of the concepts
involved meant that greater agreement might be unfeas-
ible, or exclude a meaningful definition. Similarly, less
than 30% agreement was considered to represent con-
sensus about excluding items.
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A web-based questionnaire was developed using Survey-
Monkey (http://www.surveymonkey.com ). Each expert
was sent an email inviting them to take part in the study
and a link to access the questionnaire on the Survey-
Monkey website.
In this round, we asked about the usefulness of items
found in published screening tools developed to identify
pain with neuropathic characteristics [29], and which of
these individual items “should be included in an instru-
ment to be utilised in epidemiological research”. Partici-
pants were to choose whether items were essential to
include, not essential to include, or whether items
should not be included. They were also asked to specify
any other essential items.
A further free text question asked participants “In your
opinion, when does neuropathic pain become “refrac-
tory”? Please list the crucial features that you consider
would categorise a patient as having “refractory neuro-
pathic pain”.
Second round
The results of round one were fed back to each of the par-
ticipants by email, along with a link to the round 2 ques-
tionnaire. This questionnaire asked participants to consider
their agreement about the inclusion of all of the items that
were included in round 1. Content analysis of the free text
responses to the question on the features that characterise
refractory NeuP was conducted to identify common attri-
butes to be included in a possible definition. The attributes
that were identified were: “Minimum duration of neuro-
pathic pain”, “Number of drugs of known effectiveness for
neuropathic pain tried”, “What might comprise an ad-
equate trial for neuropathic pain treatment?”, “Outcome of
treatment” and “Usefulness of other non-drug therapies”.
Specific levels within each of these attributes were also gen-
erated from the free text responses (shown in Table 1).
Agreement was sought (from 1= strongly agree to
5 = strongly disagree) on whether individual items should
be included in the definition of neuropathic pain, and
for each of the attributes that might determine when this
was refractory.
Finally, we asked about any perceived difference be-
tween the terms “Refractory Neuropathic Pain” and
“Pharmacoresistant Neuropathic Pain”, and whether par-
ticipants had any preferred terms or further comments
about the study.
Third round
Individual and group responses were fed back to each
participant and they were asked for a final time to indi-
cate their level of agreement with each of the compo-
nents to be incorporated into a working definition of
refractory neuropathic pain.Ethical approval
This study was approved by Ethics Review Board of the
College of Life Sciences and Medicine, University of
Aberdeen.
Results
Of the forty invited experts, six indicated that they were
not eligible for the study. Twenty-five of the other
experts (73.5%) completed the Round 1 questionnaire.
Response rates throughout each round of the study are
shown in Figure 1. In total nineteen experts returned
completed questionnaires for all three rounds of the Del-
phi survey. No further participants were sought as the
sample had achieved an “optimal size” for a Delphi study
[18,20]. Participants in round one (n = 25) represented a
range of medical and research disciplines (including
neurology, epidemiology, anaesthetics, pain medicine,
and neuropharmacology) and were based in nine coun-
tries (thirteen were from the UK, seven participants were
from five other European countries, four were from
North America and one from Australasia).
Items to be included in the definition of neuropathic pain
The level of agreement after three rounds for items to be
included in a case definition instrument for neuropathic
pain in epidemiology research is shown in Figure 2.
There was consensus (with at least 70% of participants
agreeing or strongly agreeing) that six items about the
presence of pain with the following characteristics should
be included: “prickling, tingling, pins & needles”, “pain
evoked by light touch”, “electric shocks or shooting pain”,
“hot or burning” pain, “a relevant patient history”, and
“brush allodynia on self-examination”. There was con-
sensus (less than 30% agreeing or strongly agreeing) that
eleven items should not necessarily be included. A fur-
ther six items produced mixed responses and consider-
able uncertainty about their inclusion (Table 2).
Definitions of refractory neuropathic pain
All participants in Round 1 completed the question
about when neuropathic pain becomes “refractory
neuropathic pain”. Some examples of the free text
responses are shown in Table 3. Content analysis of all of
the responses enabled attributes and levels to be identi-
fied for incorporation into the Round 2 questionnaire
(see above).
Minimum duration of neuropathic pain
There was no clear agreement on the minimum duration
of NeuP for it to become refractory (Table 1, Figure 3a).
However, there was clear consensus that three months
was an insufficient period of time, as 17/19 (89.5%) of
the experts disagreed or strongly disagreed that NeuP
could be said to be refractory after this length of time.
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many (8/19, 42.1%) considered that duration was not
relevant to determining refractory neuropathic pain
(Table 1, Figure 3a).Table 1 Attributes and levels identified for consideration in d
subsequent consensus among participants
Median (/5)
Minimum duration of NeuP
Three months 4.00
Six months 3.00
More than one year 2.00
Duration irrelevant 3.00
Minimum number of drugs of known effectiveness for
NeuP tried
Two drugs 4.00
Three drugs 2.00
Four drugs 2.00
More than four drugs 1.00
An adequate trial of NeuP treatment
One week 5.00
One month 3.00
Three months 2.00
Until adverse effects prevent adequate dosage 1.00
Outcomes of pain treatment
Pain levels of 5 or more on a 0–10 pain scale 2.00
Less than 30% pain intensity reduction 2.00
No period of pain remission 2.00
An increase in pain severity 2.00
Quality of life remains significantly affected by pain
(e.g. sleep, activity limitations, mood, disability)
2.00
Usefulness of other non-drug therapies
Non-pharmacological therapies must be tried before
neuropathic pain is considered refractory (e.g. TNS, physical
therapy, psychological therapy, relaxation)
2.00
No response to spinal cord stimulator 4.00
*1 = strongly agree to 5 = strongly disagree, lower mean/ median score = higher agrNumber of drugs of known effectiveness for neuropathic
pain tried
There was good agreement that four (16/18, 89% of par-
ticipants strongly agreed/ agreed), or more than fouretermining refractoriness of neuropathic pain, and
* Mean* Level of consensus,%
(n)
Final consensus on
inclusion/exclusion (>70%)
4.05 89.5% (17) disagree/
strongly disagree
YES
2.89 36.8% (7) strongly agree/
agree
NO
2.53 52.6% (10) strongly
agree/agree
NO
3.05 42.1% (8) strongly agree/
agree
NO
3.83 72.2% (13) disagree/
strongly disagree
YES
2.44 66.7% (12) strongly
agree/agree
NO
1.78 88.9% (16) strongly
agree/agree
YES
1.39 94.5% (17) strongly
agree/agree
YES
4.78 100% (18) disagree/
strongly disagree
YES
3.17 31.6% (6) strongly agree/
agree
NO
2.06 83.5% (15) strongly
agree/agree
YES
1.63 89.5% (17) strongly
agree/agree
YES
2.61 83.3% (15) strongly
agree/agree
YES
2.06 88.9% (16) strongly
agree/agree
YES
2.12 82.4% (14) strongly
agree/agree
YES
1.78 77.8% (14) strongly
agree/agree
YES
1.83 83.3% (15) strongly
agree/agree
YES
2.58 63.2% (12) strongly
agree/agree
NO
3.89 73.7% (14) disagree/
strongly disagree
YES
eement.
Selection and recruitment of panel experts
40 international expertsin neuropathic pain invited to participate by email
            First round Delphi questionnaire sent to 40 experts 
25 completed first round web-based questionnaire 
6 responded saying they were ineligiblei.e.were “active abstainers”,
9 did not respond 
Response rate round 1= 25/34, 73.5% 
Results of first round analysed 
Summary of results for group responses prepared for second round survey
            Second round Delphi questionnaire sent to 25 experts 
20 completed second round questionnaire 
2 declined to participate further (too busy),
3 did not respond 
Response rate round 2 = 20/25, 80.0%
Results of second round analysed 
Summary of results for individual and group responses prepared for third-round 
survey
            Third round Delphi questionnaire sent to 20 experts 
19 completed the third round questionnaire 
1 did not respond 
Response rate round 3 =19/20, 95%
Overall response rate for 3 rounds = 19/34, 56%
Results analysed: degree of consensus on items to be included in a case definition 
instrument for use in epidemiology research, and components for a working 
definition of refractory neuropathic pain 
Figure 1 Flowchart of participants in the study.
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agreed) of known effectiveness for neuropathic pain had
to be tried before it became “refractory” (Table 1 /
Figure 3b). Two thirds of participants indicated that a
trial of three neuropathic pain drugs was sufficient, and
there was consensus (13/18, 72.2% disagreed/strongly
disagreed) that two drugs were insufficient.An adequate trial of neuropathic pain treatment
There was consensus that at least three months’ trial of
each neuropathic pain treatment was necessary (15/18,
83.3% of participants), or treatment until adverse effectsprevented adequate dosage (17/19, 89.4% of participants)
before it could be considered refractory.
Outcome of treatment
There was consensus that any of the listed outcomes of
treatment was sufficient to render neuropathic pain re-
fractory: persistence of pain, failure to reduce pain inten-
sity or severity significantly, an increase in pain severity,
or persistently reduced quality of life (Figure 3d).
Usefulness of other non-drug therapies
Although 12/19 (63%) participants agreed that non-
pharmaceutical therapies (included therapies such as
Figure 2 Agreement after three rounds with items about pain characteristics that should be included in a neuropathic pain case
definition tool for epidemiological use.
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chological therapy, relaxation) should be tried before
neuropathic pain is considered refractory, this response
did not meet the consensus level (of 70%). There was,
though, consensus (14/19, 73.7%) that trial of spinal cord
stimulation was not required before NeuP could be con-
sidered refractory.
Terminology
Sixteen participants (84.2%) agreed or strongly agreed
that there was a difference between the terms “Refrac-
tory Neuropathic Pain” and “Pharmacoresistant Neuro-
pathic Pain”, with many comments suggesting that both
terms were important in their own right.
Discussion
This study aimed to achieve consensus from an inter-
national group of experts in neuropathic pain epidemi-
ology on (1) the components of a questionnaire
instrument for identifying neuropathic pain in epidemi-
ology research, and (2) when this pain could be termed
“refractory”. Lack of consensus in the first of these has
hindered epidemiology research to date, and contributed
to the considerable variance in published prevalence
rates. This was not intended to supplant the clinical def-
inition of (possible) NeuP [30], but to allow this to bepartly operationalised in population-based research.
There has previously been no consensus on refractori-
ness, despite several publications purporting to report
on refractory neuropathic pain.
Identifying neuropathic pain
In summary, we found that a case definition instrument
for neuropathic pain should certainly include five ques-
tions about pain characteristics, and one eliciting a clin-
ical history consistent with neuropathic pain (Table 2).
An additional six items produced mixed responses from
the expert group. Given the need for brevity and focus
in most population research questionnaires, we propose
that only the six items with >70% consensus be included
in a standard case definition instrument for epidemi-
ology research. The five characteristics of pain quality
identified by survey respondents are all featured within
the three most widely used screening tools for neuro-
pathic pain (S-LANSS, DN4, painDETECT) [9,31]. The
remaining characteristic (a relevant patient history) does
not feature in these screening tools but is part of the
diagnostic algorithm advocated by Treede et al [30].
We examined these five characteristics of pain quality
against the cut-off scores within each of the screening
tools to determine which combination(s) might be used
as a case definition tool for epidemiological use:
Table 2 Case definition items to be included in a
questionnaire instrument for epidemiology research
Questions about pain characteristics:
Prickling, tingling, pins and needles
Pain evoked by light touch
Electric shocks or shooting pain
Hot or burning pain
Brush allodynia on self examination
Question eliciting a relevant patient history
Items that might be included (>30% but <70% consensus)
Questions about pain characteristics:
Numbness
Pain evoked by heat or cold
Pain continuing after stimulus
Surface pain
Pain evoked by mild pressure
Question about the site of pain
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items [32].
 S-LANSS: cut-off is score of 12 or more. Of the five
possible combinations using four items each, three
combinations reach a positive score. The remaining
two combinations score 11 [29].
 painDETECT: cut-off score is 13 or more. If three
items are rated at least 3 (strongly) and one item 4
(very strongly), a positive score is reached [8].
Based on this analysis, we propose to test the validity
of a case definition tool for epidemiological use using
any four characteristics of pain quality in combination
with questions eliciting ‘a relevant patient history’. It is
not proposed that this tool would replace detailed his-
tory and examination, which must remain as corner-
stones in the clinical setting.
Determining refractory neuropathic pain
For neuropathic pain to be considered refractory, based
on the consensus reported above, we propose that:
 It should have had a trial of treatment with at least
four drugs of known effectiveness in neuropathic
pain
 Each of these drugs should have been tried for at
least three months or until adverse effects prevent
adequate dosage
 Despite the above treatment, the intensity of pain
should have reduced by less than 30%, or should
remain at a level of at least 5 on a 0–10 scale; and/
or it should continue to contribute significantly to
poor quality of life.We propose that the duration of neuropathic pain, by
itself does, not determine whether it is refractory
(though it is clearly relevant when considering the dur-
ation of any trials of treatment). We also propose that,
while non-pharmacological treatments should be consid-
ered, and may be effective, neuropathic pain can be con-
sidered refractory even in their absence.
Strengths and limitations of the study
Delphi surveys are an established method of achieving
consensus in complex areas and/or where consensus has
not previously been able to be reached [18]. For example
previous studies have used Delphi methods to develop a
standard definition for back pain for use in prevalence
studies (a consensus of 28 experts in back pain research
from 12 countries) [33], and to develop guidelines for
the management of hip and knee osteoarthritis (a con-
sensus of 16 experts from four medical disciplines and
six countries) [27]. The composition of the expert panel
is important, and should comprise a reasonable number
of individuals, representing a widespread range of
experts in the relevant discipline(s).
The response rate to this international study was good,
with participation from 25 (73.5% of eligible) invited
experts in NeuP in round one, and from 19 (76%) of
these experts participating in all three rounds. These
included participants from a range of clinical and re-
search disciplines and a number of countries worldwide,
all of whom had been previously recognized through
international peer selection as experts in their fields.
Considerable weight can therefore be given to the items
on which clear consensus was achieved. Although the
nature of work in this area meant that most of the
respondents knew members of the research team, it is
unlikely that this would have contributed importantly to
any bias in the responses: responses were anonymous,
and there appeared to be no hesitation in expressing
forthright views. It would have been possible to include
more experts, increasing the number of responses and
their sources. We were concerned to include individuals
who had contributed importantly to the literature in this
field, and our sample represents a good selection of
these, but it is possible that including experts based in
other countries, including the developing world, would
have further enriched our responses.
It must be noted, however, that unanimity was not
achieved for any item, and there must still be room for
flexibility in designing and interpreting questionnaire
aiming to identify refractory neuropathic pain. For ex-
ample, whilst we have proposed that an adequate trial of
at least four drugs is required before NeuP should be
considered “refractory”, good consensus was nearly
achieved (66.7%) on a trial of three drugs. Indeed, two of
the experts approached stated their view that it was
Table 3 A selection of free text responses about a
definition of refractory neuropathic pain
“Pain that cannot be reduced to levels of 4 or less on a 1–10 scale after all
available biomedical treatments have been given and adequate try”
“Does not respond to 3 different classes of neuropathic pain drugs (TCA,>
gabapentin/ pregabalin/ opioid at established sufficient dose each for a
sufficient time”
“Duration> 6 months and unresponsive or poorly responsive to
gabapentin/ pregabalin, TCA, topical lidocaine patch, opioid”
“Persistent clinical relevant pain despite a proper trial of gabapentin or
pregabalin and a tricyclic antidepressant or a serotonin noradrenalin
reuptake inhibitor”
“When, after appropriate assessment and treatment, patients are still often
distressed and/or have activity limitations due to their NP, and also have
persistent symptoms of the type outlined above”
“Persists more than a year after original injury or lesion. Pain levels greater
than 5/10 despite adequate trial with standard class 1 or 2 drugs. Pain
significantly affects the quality of life, sleep and daily function despite
adequate therapy with pharmacological agents, physical therapy and CAM
therapies”
“Patients got insufficient pain relief after trying Pregabalin up to 450 mg/
die, amitriptyline 1 mg per kilo, oxycodone 20 mg, or could not reach the
target dosage because of adverse events. If patients have contraindications
to a TCA antidepressant they should try duloxetine 60 mg or venlafaxine
225 mg. If patients have allodynia in a small area they should also try a
lidocaine patch. If patients have Trigeminal neuralgia they should try none
of the above; they should try oxcarbazepine up to 1600 mg or
carbamazepine up to 1000 mg. If they can reach adequate dosage with
either drug and still get insufficient pain relief they should be proposed
surgery. Concerning the problem of combination therapy, I do not think we
have enough evidence to ask for it. Perhaps it may be considered when
adverse events prevent reaching the adequate dosage?”
“6 months history not responded to first line treatments (ie medication with
lidocaine, anticonvulsants, antidepressants) significant disability and
distress”
“All of the neuropathic pain beyond 3 months is chronic and all of the
neuropathic pain that persists at level of 5/10 or higher even with a single
or multiple treatment modalities is refractory”
“Resistant to any kind of pharmacological and nonpharmacological
therapy, if the drugs and doses have been tested along the common
guidelines (long and high enough)”
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questionnaire, preferring instead a clinical assessment.
We recognise the distinction between diagnosing neuro-
pathic pain using clinical assessment in order to initiate
treatment, and estimating the likelihood of neuropathic
pain in a population using proxy criteria in order to
understand epidemiological factors. Whilst we respect
the importance of rigorous clinical examination in pro-
viding a detailed assessment of neuropathic pain, we
maintain that this is not practical for research in studies
of the sample size required for accurate epidemiology.
We are not proposing the above case definition ques-
tionnaire as a “gold standard” for neuropathic pain, but
as a rigorous consensus, for research purposes only,
which may now be tested in the field. Clinical examin-
ation is required to identify and assess “definite”neuropathic pain [30], (though this, too, must be based
on consensus [28] rather than any “gold standard”). It is
likely that our questionnaire will be capable of approxi-
mating “possible” neuropathic pain in large samples [30].Implications of the findings
It is anomalous that, while there was strong consensus
that “refractory” and “pharmacoresistant” neuropathic
pain are different from each other, there was consensus
(84%) on the definition of “refractory” neuropathic pain.
Although the a priori level of 70% consensus was not
achieved for the importance of trying non-pharmaco-
logical treatments, agreement approached this (63%), and
free text comments supported it, and these treatments are
therefore likely to represent the main difference between
these two concepts. Psychological treatments and pain
management programme, for example, may be effective in
neuropathic pain [34,35]. Although “pharmacoresistant”
neuropathic pain is not itself a consensus term, as our “re-
fractory” neuropathic pain is, it is based on international
consensus of a treatment paradigm of efficacious drugs
[14,36].
These and other consensuses on pharmacological
treatment, [36-39] provide an excellent basis on
which clinicians can determine the order and nature
of drugs to be used in neuropathic pain. Importantly,
they also provide a framework for inquiring about
treatment trials in epidemiology research. Whereas
most of these focus on treatment in specialist set-
tings, the recent guidelines from the National Insti-
tute for Health and Clinical Excellence (NICE) in the
UK [39] focused on the non-specialist setting. The
recommendations in the NICE guideline are broadly
consistent with determining refractoriness at the
point of specialist referral (that is, after a trial of
three or four effective drugs).
It is important, as a far as possible, to use stand-
ard definitions and tools in research, including epi-
demiology. Good epidemiology provides a foundation
basis for identifying resource, educational, treatment
and prevention strategies, and for the subsequent
evaluation of these. The use of standard tools allows
comparison between different geographical areas,
clinical and demographic subgroups, and periods of
time. This study has allowed progress towards this
for research on (refractory) neuropathic pain. Further
work is now required to validate our proposed cri-
teria in a general population study, and to review
results of such a study in comparison with existing
data, based on the range of instruments currently
available. Our proposals represent a distilled com-
promise between the best features of existing instru-
ments, with consensus from experts internationally.
a. Minimum duration of refractory NeuP b. Number of drugs of known effectiveness for NeuP that have been tried
c. Adequate trial of NeuP treatment d. Outcomes of NeuP treatment that would make it ‘’refractory’’
e. Usefulness of non-drug therapies
Figure 3 Agreement with levels of attributes identified for a definition of refractory neuropathic pain for use in epidemiology
research.
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